The passing of legislation which will cut the maximum general co-payment on Pharmaceutical Benefits Scheme (PBS) medicines from $42.50 to $30 per prescription has been welcomed by the Pharmacy Guild of Australia.
National President of the Pharmacy Guild of Australia, Professor Trent Twomey, said this was the single most significant change to the cost of, and access to, medicines since the PBS was introduced 75 years ago.
“This is a result of strong advocacy by the Pharmacy Guild on behalf of patients across the country,” Professor Twomey said.
“As primary healthcare workers, community pharmacists have for some time been hearing patients say they simply cannot afford their medicines.
“Increasingly people are being faced with the horrible decision of having to decide who in the family will go without their medicines in order to put food on the table or pay their bills.
“The Guild and community pharmacies have advocated strongly on behalf of patients for a reduction of the cost of medicines and today we thank the Federal Government for taking action which was promised as part of Labor’s election commitment.
“The reduction in the co-payment is a 30 per cent saving on the cost of each prescription. It means an individual will save $150 a year for one monthly script, or $300-$450 a year for two to three scripts a month. This is an annual saving of almost $200 million which will be put back into the pockets of Australians.”
Professor Twomey said making medicines more affordable would help reduce medication non-adherence, either through taking less of the medicine than prescribed, or not having the prescription filled at all.
“This will help reduce medicine non-adherence which directly contributes to higher healthcare costs, including preventable hospital admissions and readmission,” he said.
“In addition to increasing the universality of the access to medicines, this is a big step in addressing cost of living pressures and I congratulate the Government on acting so quickly to fulfil this election promise.”
The Guild partnered with a coalition of health bodies including the Australian Patients Association, Chronic Pain Australia and Musculoskeletal Australia to advocate on behalf of their patients.
Chief Executive Officer of the Australian Patients Association Stephen Mason said that the success of the campaign would benefit thousands of needy patients. These are patients who could not afford their prescription medications but will now benefit when the cuts commence on 1 January 2023.
Chief Executive Officer of Musculoskeletal Australia Rob Anderson said MSK was hearing from people contacting its National Helpline that, with regular housing interest rate increases and the increasing cost of living pressures, they were struggling to afford the medicines they so desperately needed to manage their conditions. The reduction in the patient co-payment must be implemented as a priority and MSK applauded the Government for the steps taken today.
President of Chronic Pain Australia, Fiona Hodson said the reduction in the co-payment would be welcome news to the one in five Australians living with chronic pain. Medicine affordability was a key issue for these patients as they managed their complex and chronic conditions.
